Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancer
Expert clinical centers already involved worldwide in this new Innovation Access Program
Marseille, France, May 11, 2021 - HalioDx SAS, the immuno-oncology diagnostics company pioneering the immunological diagnosis of cancers, announced today that Immunoscore® is now available through an Innovation Access Program for the management of locally advanced rectal cancer (LARC). In this new indication, Immunoscore® has a strong prognostic value and could support the clear-cut transition in therapeutic strategy: organ preservation in patients with locally advanced rectal cancer with a good prognosis.
In rectal cancer, where no standardized biomarker is available to personalize treatment, Immunoscore® is an independent parameter that is more informative than pre- and post-neoadjuvant treatment imaging for predicting disease-free survival.
El Sissy et al.recently published a study in Clinical Cancer Research where researchers assessed whether Immunoscore® could predict response to neoadjuvant treatment in different LARC patient cohorts and a validation "Watch and Wait" cohort. The researchers found that combining Immunoscore® with imaging post-neoadjuvant treatment can identify patients with a complete clinical response who could benefit from the organ preservation strategy. Strikingly, in the "Watch and Wait" cohort, nearly 100% of patients with a high Immunoscore achieved a good response to therapy, and all avoided relapse.
Dr. John Low Seng Hooi, MBBS, MRCP, FRCR, FRCP, FAMS, AM, Clinical Oncologist at Pantai Hospital Kuala Lumpur, Malaysia, added: “To complete clinical assessment, Immunoscore® could rapidly become the precision tool we need for supporting our clinical decisions. We are delighted to implement Immunoscore® in our practice through this Innovation Access Program with HalioDx.”
Dato’ Dr. Meheshinder Singh, founder of the Colorectal Cancer Survivorship Society Malaysia, and past President of the Malaysian Society of Colorectal Surgeons, Colorectal surgeon at Pantai Hospital Kuala Lumpur, Malaysia, commented: “Colorectal Cancer is the most common cancer in men and number two cancer in women in Malaysia. At PHKL, we are deeply committed to improving quality of care in locally advanced rectal cancer patients."
Vincent FERT, CEO of HalioDx, concluded: “We are very pleased to partner with oncologists, surgeons and pathologists committed to advance locally advanced rectal cancer patient management. Our Innovation Access Program leverages our Immunoscore® technology platform, already in the ESMO guidelines for colon cancer, that measure the host immune response at the tumor site in a spatially resolved manner enabling informed medical decisions.”
To get further information on Immunoscore® Innovation Access Program in LARC, please contact us at firstname.lastname@example.org